Incyte Corporation Stock Sees Short Interest Drop 16.2%

The most recent short interest data has been released by the NASDAQ for the 05/31/2013 settlement date, which shows a 3,637,967 share decrease in total short interest for Incyte Corporation ( INCY), to 18,801,390, a decrease of 16.21% since 05/15/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for INCY at the 05/31/2013 settlement increased to 1,211,892, as compared to 1,027,666 at the 05/15/2013 report. That brought "days to cover" down to 15.51, a 28.95% decrease from the 21.84 days to cover calculated at the previous short interest data release.

The 10 Most Shorted Stocks of the Dow »

The below chart shows the historical "days to cover" for INCY at previous short interest release dates:

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where INCY had been shorted as a hedge.

The chart below shows the one year performance of INCY shares, versus its 200 day moving average. Looking at this chart, INCY's low point in its 52 week range is $15.43 per share, with $26.30 as the 52 week high point — that compares with a last trade of $21.63.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)